AG
DRNA

Aperio Group’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Aperio Group’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$287K Buy
+13,025
New +$287K ﹤0.01% 2199

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Aperio Group's DRNA Position: Q4 2020 in Review

Aperio Group opened a new position in Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2020: 13,025 shares worth $287K. The stake represents ﹤0.01% of the portfolio and ranks #2199 among its holdings.

173 funds tracked by Wall St. Rank hold DRNA as of Q4 2020.

  • Aperio Group held 13,025 shares of Dicerna Pharmaceuticals, Inc. worth $287K as of Q4 2020.
  • Dicerna Pharmaceuticals, Inc. was a new Aperio Group position in Q4 2020.
  • Dicerna Pharmaceuticals, Inc. made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2199 holding.
  • 173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.